This study demonstrates that ARS and its derivatives—ART, DHA, ARM, ARE, and ARO—exhibit therapeutic potential for AD by targeting shared molecular pathways, particularly MAPK14 and MAPK10. Here, CYP19A1 is linked to Alzheimer disease.